IMVT Stock Analysis: Immunovant | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 6.944m USD | 12M Return: 88.2% | US45258J1025 | Charts, Fundamentals & Technical Analysis

Monoclonal Antibody, Autoimmune Disease, Immunology, Biologics
Total Rating 42
Safety 28
Buy Signal -1.33
Biotechnology
Industry Rotation: -22.5
Market Cap: 6.94B
Avg Turnover: 51.5M
Risk 3d forecast
Volatility56.6%
VaR 5th Pctl9.18%
VaR vs Median-1.47%
Reward TTM
Sharpe Ratio1.26
Rel. Str. IBD75.9
Rel. Str. Peer Group63.7
Character TTM
Beta0.840
Beta Downside0.743
Hurst Exponent0.448
Drawdowns 3y
Max DD69.88%
CAGR/Max DD-0.07
CAGR/Mean DD-0.14
EPS (Earnings per Share) EPS (Earnings per Share) of IMVT over the last years for every Quarter: "2021-09": -0.35, "2021-12": -0.36, "2022-03": -0.41, "2022-06": -0.35, "2022-09": -0.41, "2022-12": -0.49, "2023-03": -0.46, "2023-06": -0.57, "2023-09": -0.45, "2023-12": -0.36, "2024-03": -0.52, "2024-06": -0.6, "2024-09": -0.74, "2024-12": -0.76, "2025-03": -0.64, "2025-06": -0.71, "2025-09": -0.65, "2025-12": -0.54, "2026-03": -0.67, "2026-06": -0.75,
Last SUE: -0.93
Qual. Beats: -1
Revenue Revenue of IMVT over the last years for every Quarter: 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 1.5, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0.16, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: 0, 2026-06: 7.095,
Last SUE: 4.00
Qual. Beats: 1

Warnings

Strong Share Dilution
Beneish M-Score Likely Earnings Manipulation
Altman Z'' In Financial Distress Zone
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 7.3 years of data

Jan -11.0% 40
Feb -4.5% 17
Mar -10.8% 47
Apr -1.3% 30
May -0.4% 15
Jun -0.3% 6
Jul +6.2% 28
Aug -0.5% 9
Sep +9.0% 37
Oct +11.1% 17
Nov +3.9% 35
Dec +7.4% 20

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: IMVT Immunovant

Immunovant, Inc. is a clinical-stage immunology company developing targeted therapies for patients with autoimmune diseases. The company is headquartered in Durham, North Carolina, was founded in 2018, and trades on NASDAQ under the ticker IMVT within the Health Care sector (Biotechnology sub-industry).

Its lead candidate, IMVT-1402, is a human monoclonal antibody designed to inhibit the neonatal fragment crystallizable (FcRn) receptor, a mechanism being explored across multiple autoimmune indications including Graves disease, rheumatoid arthritis, Sjögrens disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. As a clinical-stage biopharmaceutical company, Immunovant is focused on advancing drug candidates through preclinical and clinical development rather than generating commercial product revenue, which is typical for firms at this stage of the biotech lifecycle.

Immunovant operates as a subsidiary of Roivant Sciences Ltd., reflecting the Roivant hub-and-spoke model in which a parent company establishes focused subsidiaries to develop individual therapeutic programs. With a mid-cap market capitalization, IMVT sits among the larger publicly traded clinical-stage immunology developers.

Headlines to Watch Out For
  • IMVT-1402 Phase 3 trial readout in myasthenia gravis
  • Competition intensifies from argenxs Vyvgart in FcRn market
  • Cash burn widens as Roivant funds pipeline expansion
Piotroski VR-10 (Strict) 1.0
Net Income: -538.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.49 > 0.02 and ΔFCF/TA 14.54 > 1.0
NWC/Revenue: 10.3k% < 20% (prev 374k%; Δ -364k% < -1%)
CFO/TA -0.49 > 3% & CFO -414.3m > Net Income -538.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.27 > 1.5 & < 3
Outstanding Shares: last quarter (205.5m) vs 12m ago 20.29% < -2%
Gross Margin: 94.24% > 18% (prev -134.4%; Δ 228.6% > 0.5%)
Asset Turnover: 0.94% > 50% (prev 0.02%; Δ 0.91% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 0.20
A: 0.86 (Total Current Assets 851.2m - Total Current Liabilities 117.1m) / Total Assets 852.5m
B: -2.23 (Retained Earnings -1.90b / Total Assets 852.5m)
C: -0.71 (EBIT TTM -538.9m / Avg Total Assets 757.0m)
D: 6.28 (Book Value of Equity 735.4m / Total Liabilities 117.1m)
Altman-Z'' = 0.20 = B
Beneish M 1.00
DSRI: 0.10 (Receivables 697k/1.94m, Revenue 7.09m/160k)
GMI: 1.00 (fallback, negative margins)
AQI: 0.08 (AQ_t 0.00 / AQ_t-1 0.01)
SGI: 44.34 (Revenue 7.09m / 160k)
TATA: -0.15 (NI -538.2m - CFO -414.3m) / TA 852.5m)
Beneish M = 26.75 (Cap -4..+1) = D
What is the price of IMVT shares?

As of October 09, 2026, the stock is trading at USD 30.26 with a total of 1,755,411 shares traded. Over the past week, the price has changed by -10.07%, over one month by -23.53%, over three months by -24.93% and over the past year by +88.24%.

Current recommended Stop Loss: 28.50 (which is 5.8% or 1.3 ATR below the current price).

Is IMVT a buy, sell or hold?

Immunovant has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy IMVT.

  • StrongBuy: 11
  • Buy: 2
  • Hold: 4
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the IMVT price?
Analysts Target Price 48.9 61.5%
Immunovant (IMVT) - Fundamental Data Overview as of 06 October 2026
Market Cap USD = 6.94b (6.94b USD * 1.0 USD.USD)
P/B = 9.6986
Revenue TTM = 7.09m USD
EBIT TTM = -538.9m USD
EBITDA TTM = -538.5m USD
 Long Term Debt = unknown (none)
 Short Term Debt = 72.0k USD (from shortTermDebt, last fiscal year)
Debt = 72.0k USD (from shortLongTermDebtTotal, last fiscal year) (leases 72.0k already included)
Net Debt = -797.7m USD (calculated: Debt 72.0k - CCE 797.8m)
Enterprise Value = 6.15b USD (6.94b + Debt 72.0k - CCE 797.8m)
 Interest Coverage Ratio = unknown (Ebit TTM -538.9m / Interest Expense TTM 0.0)
 EV/FCF = -14.84x (Enterprise Value 6.15b / FCF TTM -414.3m)
FCF Yield = -6.74% (FCF TTM -414.3m / Enterprise Value 6.15b)
 FCF Margin = -5.84k% (FCF TTM -414.3m / Revenue TTM 7.09m)
 Net Margin = -7.59k% (Net Income TTM -538.2m / Revenue TTM 7.09m)
 Gross Margin = 94.24% ((Revenue TTM 7.09m - Cost of Revenue TTM 409k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.21 (Enterprise Value 6.15b / Total Assets 852.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 72.0k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -425.7m (EBIT -538.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.27 (Total Current Assets 851.2m / Total Current Liabilities 117.1m)
Debt / Equity = 0.00 (Debt 72.0k / totalStockholderEquity, last quarter 735.4m)
 Debt / EBITDA = 1.48 (negative EBITDA) (Net Debt -797.7m / EBITDA -538.5m)
 Debt / FCF = 1.93 (negative FCF - burning cash) (Net Debt -797.7m / FCF TTM -414.3m)
 Total Stockholder Equity = 773.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -71.10% (Net Income -538.2m / Total Assets 852.5m)
RoE = -69.59% (Net Income TTM -538.2m / Total Stockholder Equity 773.5m)
RoCE = -73.28% (EBIT -538.9m / Capital Employed (Total Assets 852.5m - Current Liab 117.1m))
 RoIC = -57.92% (negative operating profit) (NOPAT -425.7m / Invested Capital 735.1m)
 WACC = 8.94% (E(6.94b)/V(6.94b) * Re(8.94%) + D(72.0k)/V(6.94b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.29 | Cagr: 16.65%
 [DCF] Fair Price = unknown (Cash Flow -414.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.93 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.72 | Chg30d=-37.33% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-12-31): EPS=-0.67 | Chg30d=-50.50% | Revisions=-25% | Analysts=3
EPS current Year (2027-03-31): EPS=-2.84 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=-15.1% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-2.75 | Chg30d=-23.96% | Revisions=-50% | GrowthEPS=+3.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -73% (up=0, down=8)